From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, ...

People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.

AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...

Researchers Identify a Potential Biomarker of Parkinson's Disease Progression Nov. 12 ... are detected in blood once symptoms have started in Lewy's body diseases, ... July 23, 2024 ...

From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, scientists were able to identify ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow the progression of Parkinson’s disease motor symptoms in a Phase III trial. The University College London (UCL) in the UK ...

Parkinson's Disease Treatment Market Aging Populations and Advancements in Deep Brain Stimulation, Gene Therapy, and Medications Fuel Marke ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...